Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNET trial in amyotrophic lateral sclerosis
NL-OMON60801Phase 3Completed
- Sponsor
- TRICALS
- Start
- Sep 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Lithium with Placebo (2 arms). Primary endpoint: Overall survival. Started Sep 2021; status: completed.
02
Drugs
lithium
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON60801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60801.